Abstract
In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Current Medicinal Chemistry
Title: Arylpiperazines with Affinity Toward a1-Adrenergic Receptors
Volume: 9 Issue: 13
Author(s): F. Manetti, F. Corelli, G. Strappaghetti and M. Botta
Affiliation:
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Abstract: In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Export Options
About this article
Cite this article as:
Manetti F., Corelli F., Strappaghetti G. and Botta M., Arylpiperazines with Affinity Toward a1-Adrenergic Receptors, Current Medicinal Chemistry 2002; 9 (13) . https://dx.doi.org/10.2174/0929867023369961
DOI https://dx.doi.org/10.2174/0929867023369961 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1
Current Pharmaceutical Design Isolated Unilateral Tongue Oedema: The Adverse Effect of Angiotensin Converting Enzyme Inhibitors
Current Drug Safety Basal Septal Hypertrophy
Current Cardiology Reviews Editorial:Circulating Biomarkers in Cardiovascular Diseases – A Field of Theoretical Research or Realistic Clinical Application?
Current Pharmaceutical Biotechnology Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Cardiovascular Disease in Primary Sjögren’s Syndrome
Reviews on Recent Clinical Trials Central Blood Pressure in Chronic Kidney Disease: Latest Evidence and Clinical Relevance
Current Hypertension Reviews Improved Methods of Extraction and In Vitro Evaluation of Antimicrobial Potential of Stem Bark of Terminalia arjuna
Current Biochemical Engineering (Discontinued) Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Deep Penetration of Nanoparticulate Drug Delivery Systems into Tumors: Challenges and Solutions
Current Medicinal Chemistry Marine-Derived Bioactive Peptides as New Anticoagulant Agents: A Review
Current Protein & Peptide Science K+ Channels of Müller Glial Cells in Retinal Disorders
CNS & Neurological Disorders - Drug Targets Role of Oxidative and Nitrosative Stress, Longevity Genes and Poly(ADPribose) Polymerase in Cardiovascular Dysfunction Associated with Aging
Current Vascular Pharmacology Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews Diacylglycerol Kinase Inhibition and Vascular Function
Current Enzyme Inhibition Effect of Ouabain on the Immune System
Current Hypertension Reviews Pharmacological Effects of Biotin in Animals
Mini-Reviews in Medicinal Chemistry NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry Association of Lipoprotein-associated Phospholipase A2 Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys
Cardiovascular & Hematological Agents in Medicinal Chemistry